Price
$114.66+1.51%Social Signal Score
Analyst Ratings
29 analystsRevenue
$729.69M+33.14%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Prahlad R. Singh
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 11,000
- Beta
- 1.09
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 3.26
Financials
Revenue
$729.69M+33.1%Net Income
$51.82M-9.9%EBITDA
$188.56M+76.5%Free Cash Flow
$180.87M+179.9%EPS (diluted)
$0.47-10.0%Shares Outstanding (diluted)
111.75M+1.5%Operating Expenses
$327.55MCash & Debt
$1.02BReturn of Capital
$23.81MRevenue by Segment (annual)
$2.86BDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.86B | $241.68M | $2.08 |
| 2024 | $2.76B | $295.83M | $2.41 |
| 2023 | $2.75B | $-118.38M | $-0.95 |
| 2022 | $3.31B | $569.18M | $4.51 |
| 2021 | $3.83B | $943.16M | $8.12 |
| 2020 | $3.78B | $728.10M | $6.53 |
| 2019 | $2.88B | $227.56M | $2.05 |
| 2018 | $2.78B | $238.79M | $2.16 |
| 2017 | $2.26B | $113.02M | $1.03 |
| 2016 | $2.12B | $233.68M | $2.13 |
| 2015 | $2.10B | $212.45M | $1.89 |
| 2014 | $2.24B | $158.04M | $1.40 |
| 2013 | $2.17B | $167.92M | $1.50 |
| 2012 | $2.12B | $68.44M | $0.60 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RVTY's reported EPS growth of 10.0% a year over 13 years.
- EPS in 5 years
- $3.44
- Implied price
- $161.58
- Return from $151.53
- 1.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $80.33 — -47.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 33 | 40 | 47 | 54 | 61 |
|---|---|---|---|---|---|
| 0.0% | -14.2% | -10.8% | -7.9% | -5.3% | -3.0% |
| 5.0% | -9.9% | -6.4% | -3.3% | -0.6% | 1.9% |
| 10.0% | -5.6% | -1.9% | 1.3% | 4.1% | 6.7% |
| 15.0% | -1.3% | 2.5% | 5.9% | 8.9% | 11.6% |
| 20.0% | 3.0% | 7.0% | 10.5% | 13.6% | 16.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
163+1533.33%Social Signal Score
Mentions (19)
- Newszacks.com·3d ago·Positive
Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock? Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsbusinesswire.com·4d ago·Neutral
Revvity to Hold Earnings Call on November 3, 2026 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio web…
View source ↗ - Newszacks.com·6d ago·Neutral
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
View source ↗ - Newszacks.com·10d ago·Neutral
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
View source ↗ - Newszacks.com·20d ago·Neutral
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength? Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·21d ago·Positive
Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·24d ago·Negative
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
View source ↗ - Newszacks.com·25d ago·Positive
Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsseekingalpha.com·26d ago·Neutral
Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
View source ↗ - Newsbusinesswire.com·27d ago·Negative
…y to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models …
View source ↗ - Newszacks.com·32d ago·Positive
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich? Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
View source ↗ - Newszacks.com·34d ago·Positive
What Makes Revvity (RVTY) a New Buy Stock Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·42d ago·Negative
Is the Options Market Predicting a Spike in Revvity Stock? Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·53d ago·Neutral
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
View source ↗ - Newsbusinesswire.com·56d ago·Neutral
Revvity to Present at Upcoming Investor Conferences WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird's 20
View source ↗ - Newsbusinesswire.com·57d ago·Neutral
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregna
View source ↗ - Newsmarketbeat.com·58d ago·Negative
Revvity Q2 Earnings Call Highlights Revvity NYSE: RVTY reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $1.29 per share
Typical surprise +3.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$1.41 vs $1.21beat
- Tue, May 5$1.06 vs $1.02beat
- Mon, Feb 2$1.70 vs $1.57beat
- Mon, Oct 27$1.18 vs $1.14beat
- Mon, Jul 28$1.18 vs $1.14beat
- Mon, Apr 28$1.01 vs $0.96beat
Estimates and results for RVTY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RVTY officers and directors.
- Bought
- —
- Sold
- $6.1m
0 trades
19 trades
- Gonzales Anitasold
- Krakowiak Maxwellsold
- Vohra Tajinder Ssold
- Gonzales Anitasold
- Gonzales Anitasold
- Victor Miriamesold
- Mcmurry-heath Michellesold
- Singh Prahlad R.sold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2026 (36d later)Buy$15,001 - $50,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 11, 2026 (10d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 10, 2025 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 12, 2025 (30d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 15, 2025 (23d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 11, 2025 (30d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2025 (12d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 21, 2025 (21d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (8d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (15d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (20d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.